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Background: The new combination of moxifloxacin HCl and cefixime trihydrate is approved for the treatment of
lower respiratory tract infections in adults. At initial formulation development and screening stage a fast and
reliable method for the dissolution and release testing of moxifloxacin and cefixime were highly desirable. The zero
order overlaid UV spectra of moxifloxacin and cefixime showed >90% overlapping. Hence, simple, accurate precise
and validated two derivative spectrophotometric methods have been developed for the determination of
moxifloxacin and cefixime.
Methods: In the first derivative spectrophotometric method varying concentration of moxifloxacin and cefixime
were prepared and scanned in the range of 200 to 400 nm and first derivative spectra were calculated (n = 1). The
zero crossing wavelengths 287 nm and 317.9 nm were selected for determination of moxifloxacin and cefixime,
respectively. In the second method the first derivative of ratio spectra was calculated and used for the
determination of moxifloxacin and cefixime by measuring the peak intensity at 359.3 nm and 269.6 nm respectively.
Results: Calibration graphs were established in the range of 1–16 μg /mL and 1–15 μg /mL for both the drugs by
first and ratio first derivative spectroscopic methods respectively with good correlation coefficients. Average
accuracy of assay of moxifloxacin and cefixime were found to be 100.68% and 98 93%, respectively. Relative
standard deviations of both inter and intraday assays were less than 1.8%. Moreover, recovery of moxifloxacin and
cefixime was more than 98.7% and 99.1%, respectively.
Conclusions: The described derivative spectrophotometric methods are simple, rapid, accurate, precise and
excellent alternative to sophisticated chromatographic techniques. Hence, the proposed methods can be used for
the quality control of the cited drugs and can be extended for routine analysis of the drugs in formulations.
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Ultraviolet (UV) – visible spectroscopic method of analysis
is widely used in the analysis of drugs in pharmaceutical
formulations and for dissolution and disintegration studies
due to its good sensitivity and cost effectiveness. In last
three decades, derivative spectrophotometry has been
extensively used in the determination of drugs in multi
components having overlapping spectra, which eliminates
interference from formulation matrix by using the
zero-crossing techniques [1-4]. Ratio-spectra derivative* Correspondence: mattimarad@gmail.com
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© 2012 Attimarad et al.; licensee Chemistry Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumspectrophotometric method is another useful technique
for the estimation of drugs in their mixtures [5-8].
The derivative spectra methods allows us to use the
wavelength of highest value of maxima or minima sig-
nals. Moreover, the presence of a more number of max-
ima and minima wavelengths gives an opportunity to
select a particular wavelength for determination of active
compounds without the interference from other com-
pounds or formulation excipients. The derivative spectra
methods are developed for simultaneous determination
of moxifloxacin Hydrochloride (MOX) and cefixime tri-
hydrate (CEF), a newly FDA approved multicomponent
formulation for combination therapy.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.




methyl)oxime]trihydrate, Scheme 1) is semi synthetic,
oral, third-generation cephalosporin antibiotic. Cefixime
is active against a very wide spectrum of bacteria, act by
inhibiting cell wall formation [9]. Literature reports
many analytical methods for the determination of CEF
in single and in combination with other drug, using UV
spectroscopy [10,11] spectrofluorometry [12] HPLC
[13-20] and HPTLC [21].
Moxifloxacin (1-cyclopropyl-7-(S, S)-2, 8-diazabicyclo
(4.3.0)-non-8-yl-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-
3-quinoline carboxylic acid hydrochloride, MOX,
Scheme 1) is antimicrobial agent, it is fourth generation
fluoroquinolone antibiotic. The mechanism of action in-
volve inhibition of an enzyme topoisomerase II (DNA
gyrase), which is essential for bacterial DNA replication
[22]. Several analytical methods have been reported for
the determination of MOX in formulations and bio-
logical fluids, such as UV spectroscopic methods [23,24],
Spectrofluorometry [25], RP-HPLC [26-30], and capillary
electrophoresis [31,32].
The new combination of MOX and CEF is approved by
Central Drugs Standard Control Organization (CDSCO)
India for the treatment of lower respiratory tract infections
in adults. Simultaneous determination of these drugs is es-
sential in each step of initial formulation development and
screening stage of any solid dosage form. A fast and reli-
able method for the dissolution and release testing of
MOX and CEF were highly desirable. However, there are
no simple and rapid analytical methods to estimate the
drug content in the combined forms. Hence there is an ur-
gent demand to develop a simple and rapid method such
as spectroscopic method to assess the drug content in this
combination. However, the major concern for these two
drugs is the overlapping of absorption bands, which also
restricts the direct measurement using UV spectroscopy.
The objective of the current study was to develop rapid,
accurate, reproducible, validated and economical first de-












Scheme 1 Structure of Moxifloxacin HCl (a) and Cefixime trihydrate (bsimultaneous determination of MOX and CEF from pure
and in presence of formulation excipients.
Experimental
Instruments and chemicals
UV-visible spectrophotometer (Shimadzu, 1700) with UV-
probe software connected to computer was used for the
drug estimation. Quartz cuvettes (1 cm) were matched
and used for all absorbance measurements. Double dis-
tilled de-ionized water and Whatmann filter paper (no.41)
were used throughout the experimental work. The sample
of moxifloxacin certified to contain 99.81% was procured
from Micro Labs, India and Cefixime trihydrate certified
to contain 99.84% from Dr. Reddy's laboratory, India.
Moxicip tablets containing 400 mg of moxifloxacin and
suprax tablets containing 400 mg of cefixime were pur-
chased from pharmacy.
Preparation of standard stock solution
Standard stock solutions of MOX and CEF (1 mg/mL)
were prepared by dissolving 100 mg of drugs in water,
separately. The working standard solutions of the
respective drugs were prepared by serial dilution using
water.
Method development
Method-D1 (First derivative Spectrophotometric method)
In the first order derivative method, aliquots of MOX
and CEF standard stock solutions were accurately trans-
ferred in to 10 mL volumetric flasks, separately and
volumes were completed with water. All the solutions
were scanned from 200 to 400 nm in the spectrum
mode. Thus obtained absorption spectra were deriva-
tized from first to fourth order. First order derivative
(n = 1) spectra showed good sensitivity and linearity
hence the zero crossing wavelengths, 287 nm and
317.9 nm of first order derivative spectra were selected
for analysis of MOX and CEF, respectively. The calibra-














Figure 1 UV absorption spectra of Moxifloxacin (10 μg/mL,
M10), cefixime (10 μg/mL, C10) and combination (10 μg/mL
each, MC10).
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against calibration curve in quantitation mode.
Method-RD1 (First derivative of the ratio spectra)
Previously scanned absorption spectra of MOX solutions
prepared at different concentrations (1 to 15 μg/mL) in
its binary mixture with CEF was divided by the spectrum
of the standard solution of CEF (10 μg /mL in water) to
get the ratio spectra of MOX. The first derivative of the
ratio spectra were than calculated. The amount of MOX
was determined by measuring the first derivative signal
at 359.3 nm. A similar procedure was followed for differ-
ent concentrations of CEF (1 to 15 μg /mL ) with MOX
and for division spectrum of the standard solution of
MOX (8 μg /mL in water) was used. Similarly, content
of CEF was determined by measuring the first derivative
signal at 269.6 nm.
Assay of laboratory-prepared mixtures The absorption
spectrum was recorded for the laboratory prepared mix-
tures, against water as a blank. The intensity of the first
derivative spectra of the laboratory prepared mixtures
containing different ratios of MOX and CEF were mea-
sured at 287 nm and 317.9 nm respectively. The previ-
ously scanned zero order absorption spectra for the
laboratory prepared mixture were divided by the
spectrum of CEF (10 μg/mL) and by spectrum of MOX
(8 μg/mL) separately for the determination of MOX and
CEF respectively. The concentrations of MOX and CEF
were calculated from their corresponding regression
equations measuring the intensity of signals at 359.3 nm
and 269.6 nm respectively.
Analysis of MOX and CEF in presence of tablet excipients
To determine the content of MOX and CEF simultan-
eously in the presence of tablet excipients 20 tablets of
MOX 400 mg and 20 tablets of CEF 400 mg were
weighed separately and average weight was determined.
All the 40 tablets were powdered and correct amount of
powder (equivalent to 20 mg of both the drugs) was dis-
solved in water using sonicater (30 min). After filtration,
an appropriate aliquots were subjected to above methods
and the amount of MOX and CEF were determined.
Validation of the methods Newly developed methods
were validated for linearity, accuracy, precision, limits of
quantization and selectivity according to the ICH
guidance.
Linearity For linearity six different concentration of
MOX and CEF in the range of 1–16 μg/mL were ana-
lyzed. The limit of detection (LOD) and limit of quantifi-
cation (LOQ) were determined by 3.3 σ/s and 10 σ/s
criteria, respectively; where σ is the standard deviationof the analytical signal and s is the slope of the corre-
sponding calibration curve.
Accuracy Accuracy of the method was determined by
calculating recoveries of MOX and CEF by standard
addition method, in which pre-analyzed samples were
taken (5 μg/mL ) and standard drug was added at three
different levels i.e. 80%, 100% and 120%. The total
amount of MOX and CEF were estimated by using the
proposed methods in triplicate. The% recovery of the
added pure drugs were calculated as% recovery =
((Dt-Ds)/Da) X 100, where Dt is the total drug concen-
tration measured after standard addition; Ds drug con-
centration in the formulation mixture; Da drug
concentration added.
Precision Intraday and interday precision of the pro-
posed methods were determined by estimating the MOX
and CEF three times on the same day to obtain the
repeatability and on three different days to obtain the
reproducibility. Each assay was carried out on different
samples of MOX and CEF. From the obtained data per-
cent relative standard deviation (% RSD) was calculated.
Stability of the analytical solutions This was evaluated
by measuring absorbance of freshly prepared standard
and sample solutions, and repeating the measurement
after 24 h.
Results and discussion
Method development and validity
MOX and CEF possess good aqueous solubility and
showed good UV absorption, thus water has been
selected as solvent for the present analytical methods.
The zero order overlaid UV spectra of MOX and CEF
(10 μg/mL each) and their mixture obtained were shown
in Figure 1. It is evident from the figure that >90% of
Figure 2 First derivative UV absorption spectra of moxifloxacin
(10 μg/mL, M10), cefixime (10 μg/mL, C10) and combination
(10 μg/mL each MC10).
Figure 4 First derivative UV absorption spectra of cefixime (1
to 16 μg/mL).
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complexity in measuring these drugs by direct UV ab-
sorption measurement in a binary mixture.
From the zero-order spectra first to four orders
derivative spectra were obtained using digital differenti-
ation for both the drugs. First order derivative spectra of
both the drugs showed well-defined zones for determin-
ation of each analyte with a good sensitivity and linear-
ity. Spectra with higher order of derivation had lower
sensitivity and linearity, hence, only first order derivative
spectra were selected for quantitative analysis. For first
derivative spectroscopy, the spectra of the MOX and
CEF obtained by scanning in water, were changed to first
derivative spectra. For the first derivative spectra, differ-
ent wavelengths (2, 4, 8 and 10 nm) were attempted to
obtain the optimum Δλ. The results signified that 4 nm is
an optimum Δλ and this wavelength was selected and used.
The first derivative spectra of CEF present four
zero crossing at 222.1, 248.4, 379.0 nm and 287.0 nm
(Figure 2 and Figure 3). Therefore, to select most appro-
priate wavelength, MOX was determined form the labora-
tory mixture at all the four wavelength and mean recovery
and standard deviation were calculated and found to beFigure 3 First derivative UV absorption spectra of Moxifloxacin
(1 to 16 μg/mL).101 ± 2.45, 100.89 ±1.48 99.81 ± 2.68 and 100.67 ± 0.73 at
222.1, 248.2, 379.0 nm and 287.0 nm respectively. Further,
the first derivative spectra of MOX showed two zero
crossing wavelengths (317.9 nm and 333.7 nm) (Figure 2
and Figure 4). These points were tested for the determin-
ation of CEF from the binary mixture. The synthetic mix-
ture mean recovery of CEF and standard deviation were
found to be 99.5 ± 1.06 and 101.85 ±1.92 at 317.9 and
333.7 nm respectively. The 287.0 nm peak for MOX and
317.9 nm peak for CEF were selected for determination of
drug in synthetic mixture in pure and in presence of tablet
excipients due to low standard deviation and good mean
recovery. Moreover, the method was linear in the concen-
tration range of 1–16 μg /mL for both MOX and CEF
with correlation coefficient 0.9992.
The selection of the divisor concentration and the
working wavelengths were very important, hence, eight
different concentrations of CEF and MOX (2, 4, 6 . . .
and 16 μg /mL) were tried as divisors separately. It was
found that minimum noise and better selectivity were
obtained upon using 10 μg/mL of CEF spectrum and
8 μg /mL of MOX spectrum as a divisor. For the deter-
mination of MOX, the UV spectra of MOX and CEFFigure 5 Ratio spectra of MOX (1 to 15 μg/mL) using 10 μg/
mLsolution of CEF as devisor.
Figure 6 First derivative Ratio spectra of MOX (1 to 15 μg/mL), inside enlarged portion of spectra of 265 to 315 nm.
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the spectrum of 10 μg /mL CEF solution, from the spec-
tra obtained (Figure 5) first derivative spectra were cal-
culated. It is evident from the figure (Figure 6) that there
are two maxima at 283.5 and 359.3 nm and four minima
at 303.5, 377.1, 386.8 and 393.4 nm. It was found that
measured signals at these wavelengths are proportional
to the concentrations of the drug. Similarly, for deter-
mination of CEF, UV spectra of CEF standards of in-
creasing concentrations in its binary mixture with MOX
were divided by the spectrum of 8 μg /mL MOX. From
the ratio spectra obtained (Figure 7), their first deriva-
tives were calculated (Figure 8). These spectra showed
three maxima (221.3, 258.9 and 303.2 nm) and two
minima (269.6 and 316.3 nm). Further, the results also
indicated that the measured signals at these wavelengths
are proportional to the concentrations of the drug. The
wavelength of 359.3 and 269.6 nm were selected for
determination of MOX and CEF in synthetic mixtureFigure 7 Ratio spectra of CEF (1 to 15 μg/mL) using 8 μg/mL
solution of MOX as devisor.and in the presence of tablet excipients due to its low
standard deviation value and suitable mean recovery at
these wavelengths.
Linearity
Calibration graphs were established for MOX and CEF in
the concentration range 1 to 16 μg /mL at 287.0 nm for
MOX and at 317.9 nm for CEF by first derivative method.
Whereas by the first derivative of the ratio spectrum cali-
bration curves were constructed at 359.3 nm for MOX
and 269.6 nm for CEF in the range of 1 to 15 μg /mL .
The linearity of the calibration curves were validated by
the high value of correlation coefficients. The analytical
data of the calibration curves including the slope and
intercept are summarized in Tables. The proposed meth-
ods were validated as per ICH guideline and the limit of
detection (LOD) and limit of Quantization (LOQ) for
method D1 and method RD1 for both the drugs were cal-
culated (Table 1) and tested practically.Figure 8 First derivative of the ratio spectra of CEF
(1 to 15 μg /mL).
Table 3 Results of Assay of formulation by first and ratio




Method D1 Method RD1
MOX CEF MOX CEF
Table 1 Validation parameters for first and ratio first
derivative spectroscopic methods
Parameters assessed Method D1* Method RD1**
MOX CEF MOX CEF
Beer’s law range (μg /mL ) 1-16 1-16 1-15 1-15
Wavelength (nm) 287.0 317.9 359.3 269.6
Correlation Coefficent(r2) 0.9992 0.9992 0.9991 0.9993
Slope 0.00362 0.00114 0.1807 0.0109
Intercept 5.08x10-4 −4.32x10-5 −0.0196 −0.0016
LOD 0.22 0.32 0.24 0.14
LOQ 0.75 0.95 0.70 0.43
Intraday precision (%RSD) 0.87 1.35 0.92 0.80
Interday precision(%RSD) 1.56 1.79 1.38 1.18
* First derivative Spectrophotometric method. **First derivative of the ratio
spectra.
MOX-Moxifloxacin HCl, CEF- Cefixime trihydrate. %RSD : Percent Relative
Standard Deviation.
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Relatively very low % RSD for inter and intraday varia-
tions for both drugs in both methods confirms the preci-
sion of the methods (Table 1). RSD values found were
well with the acceptable range indicating that these
methods have excellent repeatability and reproducibility
in the current experimental condition.
Accuracy
The results showed that the % recovery values are
greater than 98% with low standard deviation indicating
high accuracy of the proposed analytical methods. Fur-
ther the validity and reliability of the proposed methods
were assessed by determining the mean percentage re-
covery at 80%, 100% and 120% level. The average % re-
covery ranges from 98.72 to 100.57 for MOX and CEF
form both the methods and are presented in Table 2.
Estimation in pure and in presence of tablet excipients
For quantitative analysis of MOX and CEF laboratory










Method D1 Method RD1
MOX CEF MOX CEF MOX CEF MOX CEF
5 5 4 4 101.29 99.01 98.28 99.23
5 5 5 5 98.34 100.21 100. 81 101.18
5 5 6 6 101.38 98.28 99.15 101.29
Average 100.34 99.17 98.72 100.57
± RSD (%) 1.72 0.98 0.62 1.15
*Amount of MOX and CEF in the pre-analyzed samples is 5 μg/mL.used and analyzed by first and ratio first derivative
methods. Results showed that the% amount of MOX
and CEF was found to be between 98.93 to 101.32 with
low standard deviation (Table 3).
Specificity
Since information of placebo composition is not avail-
able, the comparative study was carried out for labora-
tory mixed standards and the formulation under
investigation. When comparing the results (Table 3) of
laboratory mixed and the formulation preparation one
can conclude that the method is specific for the analyte
used and the coexisting constituents do not affect the
measurements.
Stability of the analytical solutions
Deviation from the mean initial absorbance is less than
2.4% for both MOX and CEF, which is well within the
acceptable range (not more than ± 3%) indicating the
stability of the analytical solutions.
Conclusions
A simple, rapid, accurate, and precise and nature
friendly two derivative UV spectroscopic methods were
developed for the simultaneous estimation of MOX and
CEF in bulk drugs and in the presence of tablet excipi-
ents. The recovery studies suggested non-interference of
formulations excipients in the estimation. Moreover, the
present methods were rapid as compared to sophisti-
cated chromatographic techniques, hence the proposed
methods can be used for the quality control of the cited
drugs and can be extended for routine analysis of the
drugs in their pharmaceutical preparations.Laboratory Mixture
20.1 101.82 101.75 99.13 99.62
20 101.35 100.89 101.56 98.92
20 98.88 101.31 100.71 98.25
Avg. 100.86 101.32 100.47 98.93
± RSD (%) 1.58 0.42 1.22 0.69
Tablet powder
20.1 100.4 99.12 99.01 101.13
20.1 101.74 98.95 98.91 101.01
20.2 101.12 101.7 101.61 98.56
Avg. 101.09 99.92 99.84 100.23
± RSD (%) 0.65 1.54 1.53 1.44
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